Since then, SUs and TZDs have fallen out of favor, while DPP-4is, GLP1-RAs and sodium-glucose transport protein 2 inhibitors (SGLT2is) are among the add-on therapies most commonly recommended by current guidelines for type 2 diabetes [10–12]. This evidence concerns the gene GCG and type 2 diabetes mellitus.